{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:18:00Z","timestamp":1793643480896,"version":"4.5.1"},"reference-count":64,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T00:00:00Z","timestamp":1664323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Neurological diseases can significantly reduce the quality and duration of life. Stem cells provide a promising solution, not only due to their regenerative features but also for a variety of other functions, including reducing inflammation and promoting angiogenesis. Although only hematopoietic cells have been approved by the FDA so far, the number of trials continues to expand. We analyzed 492 clinical trials and illustrate the trends in stem cells origins, indications, and phase and status of the clinical trials. The most common neurological disorders treated with stem cells were injuries of brain, spinal cord, and peripheral nerves (14%), stroke (13%), multiple sclerosis (12%), and brain tumors (11%). Mesenchymal stem cells dominated (83%) although the choice of stem cells was highly dependent on the neurological disorder. Of the 492 trials, only two trials have reached phase 4, with most of all other trials being in phases 1 or 2, or transitioning between them (83%). Based on a comparison of the obtained results with similar works and further analysis of the literature, we discuss some of the challenges and future directions of stem cell therapies in the treatment of neurological diseases.<\/jats:p>","DOI":"10.3390\/ijms231911453","type":"journal-article","created":{"date-parts":[[2022,9,28]],"date-time":"2022-09-28T22:53:19Z","timestamp":1664405599000},"page":"11453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":33,"title":["Stem Cells in Clinical Trials on Neurological Disorders: Trends in Stem Cells Origins, Indications, and Status of the Clinical Trials"],"prefix":"10.3390","volume":"23","author":[{"given":"Eugenia D.","family":"Namiot","sequence":"first","affiliation":[{"name":"Department of Neuroscience, Functional Pharmacology, Uppsala University, 75124 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenni Viivi Linnea","family":"Niemi","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Functional Pharmacology, Uppsala University, 75124 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7047-1436","authenticated-orcid":false,"given":"Vladimir N.","family":"Chubarev","sequence":"additional","affiliation":[{"name":"Advanced Molecular Technology, Limited Liable Company (LLC), 354340 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vadim V.","family":"Tarasov","sequence":"additional","affiliation":[{"name":"Advanced Molecular Technology, Limited Liable Company (LLC), 354340 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helgi B.","family":"Schi\u00f6th","sequence":"additional","affiliation":[{"name":"Department of Neuroscience, Functional Pharmacology, Uppsala University, 75124 Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,28]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1001\/jamaneurol.2020.4152","article-title":"Burden of neurological disorders across the US from 1990\u20132017: A global burden of disease study","volume":"78","author":"Feigin","year":"2021","journal-title":"JAMA Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.ncl.2018.04.001","article-title":"Epidemiology of brain tumors","volume":"36","author":"Jill","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.expneurol.2014.02.021","article-title":"The past, present and future of stem cell clinical trials for ALS","volume":"262","author":"Thomsen","year":"2014","journal-title":"Exp. Neurol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1080\/21678421.2020.1771734","article-title":"Real-world evidence of riluzole effectiveness in treating amyotrophic lateral sclerosis","volume":"21","author":"Andrews","year":"2020","journal-title":"Amyotroph. Lateral Scler Front. Degener."},{"key":"ref_5","first-page":"2314","article-title":"Stem Cells: Insights into Niche, Classification, Identification, Characterization, Mechanisms of Regeneration by Using Stem Cells, and Applications in Joint Disease Remedy","volume":"2","author":"Abofila","year":"2021","journal-title":"J. Biotech. Bioprocess"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.7196\/SAMJ.2019.v109i8b.14009","article-title":"Stem cell therapy for neurological disorders","volume":"109","author":"Alessandrini","year":"2019","journal-title":"S. Afr. Med. J."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2174\/22123946MTA33NzUey","article-title":"Transplantation of stem cells as a potential therapeutic strategy in neurodegenerative disorders","volume":"16","author":"Ebrahimi","year":"2021","journal-title":"Curr. Stem Cell Res. Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/s41419-020-02955-3","article-title":"Stem\/progenitor cell-based transplantation for retinal degeneration: A review of clinical trials","volume":"11","author":"Wang","year":"2020","journal-title":"Cell Death Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/scd.2006.0081","article-title":"Embryonic stem cells","volume":"16","author":"Biswas","year":"2007","journal-title":"Stem Cells Dev."},{"key":"ref_10","first-page":"1","article-title":"Stem cells, classifications and their clinical applications","volume":"1","author":"Barky","year":"2017","journal-title":"Am. J. Pharmacol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Trounson, A., Lomax, T.G., and Gibbons, D. (2011). Clinical trials for stem cell therapies. BMC Med., 9.","DOI":"10.1186\/1741-7015-9-52"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"829","DOI":"10.3727\/096368915X689622","article-title":"Clinical trials with mesenchymal stem cells: An update","volume":"25","author":"Squillaro","year":"2016","journal-title":"Cell Transplant."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s12015-021-10231-w","article-title":"Clinical Trials Based on Mesenchymal Stromal Cells are Exponentially Increasing: Where are We in Recent Years?","volume":"18","author":"Galderisi","year":"2021","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.18295\/squmj.2018.18.03.002","article-title":"Sources and clinical applications of mesenchymal stem cells: State-of-the-art review","volume":"18","year":"2018","journal-title":"Sultan Qaboos Univ. Med. J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1080\/14712598.2019.1671970","article-title":"Stromal vascular fraction technologies and clinical applications","volume":"19","author":"Andia","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Pereira, I.M., Marote, A., Salgado, A.J., and Silva, N.A. (2019). Filling the gap: Neural stem cells as a promising therapy for spinal cord injury. Pharmaceuticals, 12.","DOI":"10.3390\/ph12020065"},{"key":"ref_17","first-page":"57","article-title":"A concise review on the classification and nomenclature of stem cells","volume":"25","author":"Can","year":"2008","journal-title":"Turk. J. Hematol."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Bissels, U., Eckardt, D., and Bosio, A. (2013). Characterization and classification of stem cells. Regenerative Medicine, Springer.","DOI":"10.1007\/978-94-007-5690-8_6"},{"key":"ref_19","first-page":"919","article-title":"Stem cell: Basics, classification and applications","volume":"2","author":"Kuntal","year":"2014","journal-title":"Am. J. Phytomedicine Clin. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Arrighi, N. (2018). Definition and classification of stem cells. Stem Cells, Elsevier.","DOI":"10.1016\/B978-1-78548-254-0.50001-X"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Yuan, S.H., Martin, J., Elia, J., Flippin, J., Paramban, R.I., Hefferan, M.P., Vidal, J.G., Mu, Y., Killian, R.L., and Israel, M.A. (2011). Cell-surface marker signatures for the isolation of neural stem cells, glia and neurons derived from human pluripotent stem cells. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0017540"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/stem.1681","article-title":"Concise review: The surface markers and identity of human mesenchymal stem cells","volume":"32","author":"Tuan","year":"2014","journal-title":"Stem Cells"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13287-017-0598-y","article-title":"Adipose tissue-derived stromal vascular fraction in regenerative medicine: A brief review on biology and translation","volume":"8","author":"Pablo","year":"2017","journal-title":"Stem Cell Res. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.arcmed.2003.09.008","article-title":"Identification and isolation of hematopoietic stem cells","volume":"34","author":"Wognum","year":"2003","journal-title":"Arch. Med. Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1634\/stemcells.2005-0595","article-title":"Integrins are markers of human neural stem cells","volume":"24","author":"Hall","year":"2006","journal-title":"Stem Cells"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12712","DOI":"10.1111\/cpr.12712","article-title":"Immune modulation by mesenchymal stem cells","volume":"53","author":"Jiang","year":"2020","journal-title":"Cell Prolif."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2020.06.009","article-title":"Mesenchymal stem cell immunomodulation: Mechanisms and therapeutic potential","volume":"41","author":"Song","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/s41582-018-0126-4","article-title":"Exosomes\u2014beyond stem cells for restorative therapy in stroke and neurological injury","volume":"15","author":"Zhang","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"675","DOI":"10.3109\/14653249.2010.549122","article-title":"Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy","volume":"13","author":"Ikegame","year":"2011","journal-title":"Cytotherapy"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.lfs.2015.09.019","article-title":"Mesenchymal stem cells of different origin: Comparative evaluation of proliferative capacity, telomere length and pluripotency marker expression","volume":"141","author":"Kukolj","year":"2015","journal-title":"Life Sci."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.apjtm.2015.07.022","article-title":"Comparative analysis of biological characteristics of adult mesenchymal stem cells with different tissue origins","volume":"8","author":"Chen","year":"2015","journal-title":"Asian Pac. J. Trop. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.molmed.2020.04.005","article-title":"Promises and limitations of neural stem cell therapies for progressive multiple sclerosis","volume":"26","author":"Pluchino","year":"2020","journal-title":"Trends Mol. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/978-3-030-31206-0_4","article-title":"Neural stem cells","volume":"Volume 1201","author":"Tuazon","year":"2019","journal-title":"Stem Cells"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"817","DOI":"10.4252\/wjsc.v11.i10.817","article-title":"Neural stem cell transplantation therapy for brain ischemic stroke: Review and perspectives","volume":"11","author":"Zhang","year":"2019","journal-title":"World J. Stem Cells"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"696434","DOI":"10.3389\/fcell.2021.696434","article-title":"Stem cell therapies for progressive multiple sclerosis","volume":"9","author":"Smith","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"4243102","DOI":"10.1155\/2018\/4243102","article-title":"Application of stem cells and advanced materials in nerve tissue regeneration","volume":"2018","author":"Li","year":"2018","journal-title":"Stem Cells Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1177\/0963689718806846","article-title":"Mesenchymal stem cell therapy in stroke: A systematic review of literature in pre-clinical and clinical research","volume":"27","author":"Zheng","year":"2018","journal-title":"Cell Transplant."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1007\/s12975-016-0482-6","article-title":"Stem cell therapy and administration routes after stroke","volume":"7","author":"Fuentes","year":"2016","journal-title":"Transl. Stroke Res."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ford, E., Pearlman, J., Ruan, T., Manion, J., Waller, M., Neely, G.G., and Caron, L. (2020). Human Pluripotent Stem Cells-Based Therapies for Neurodegenerative Diseases: Current Status and Challenges. Cells, 9.","DOI":"10.3390\/cells9112517"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/sctm.19-0202","article-title":"Trends in mesenchymal stem cell clinical trials 2004-2018: Is efficacy optimal in a narrow dose range?","volume":"9","author":"Kabat","year":"2020","journal-title":"Stem Cells Transl. Med."},{"key":"ref_41","first-page":"140","article-title":"Umbilical cord mesenchymal stem cells in neurological disorders: A clinical study","volume":"52","author":"Miao","year":"2015","journal-title":"Indian J. Biochem. Biophys."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2002944","DOI":"10.1002\/advs.202002944","article-title":"Mesenchymal Stem Cells for Neurological Disorders","volume":"8","author":"Andrzejewska","year":"2021","journal-title":"Adv. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.reth.2018.08.001","article-title":"Mesenchymal stromal cells as a potential therapeutic for neurological disorders","volume":"9","author":"Mukai","year":"2018","journal-title":"Regen. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.neulet.2007.12.067","article-title":"Bone marrow stromal cells can be delivered to the site of traumatic brain injury via intrathecal transplantation in rabbits","volume":"434","author":"Liu","year":"2008","journal-title":"Neurosci. Lett."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1080\/08880018.2018.1532478","article-title":"High-dose chemotherapy and autologous hematopoietic stem-cell rescue for treatment of relapsed and refractory Wilms tumor: Re-evaluating outcomes","volume":"35","author":"Rossoff","year":"2018","journal-title":"Pediatric Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.3892\/mmr.2016.5852","article-title":"Hematopoietic stem cells as a tool for the treatment of glioblastoma multiforme","volume":"14","author":"Bryukhovetskiy","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_47","first-page":"453","article-title":"Human umbilical cord blood stem cells show PDGF-D\u2013dependent glioma cell tropism in vitro and in vivo","volume":"12","author":"Gondi","year":"2010","journal-title":"Neuro-oncology"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.expneurol.2005.11.027","article-title":"Vascular endothelial growth factor A contributes to glioma-induced migration of human marrow stromal cells (hMSC)","volume":"199","author":"Schichor","year":"2006","journal-title":"Exp. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3332\/ecancer.2018.822","article-title":"Adipose tissue stem cells in regenerative medicine","volume":"12","author":"Miana","year":"2018","journal-title":"Ecancermedicalscience"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/s41388-018-0477-8","article-title":"Adipose-derived stem cells enhance human breast cancer growth and cancer stem cell-like properties through adipsin","volume":"38","author":"Goto","year":"2019","journal-title":"Oncogene"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Sabol, R.A., Beighley, A., Giacomelli, P., Wise, R.M., Harrison, M.A., O\u2019donnnell, B.A., Sullivan, B.N., Lampenfeld, J.D., Matossian, M.D., and Bratton, M.R. (2019). Obesity-altered adipose stem cells promote ER+ breast cancer metastasis through estrogen independent pathways. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061419"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ymeth.2017.09.007","article-title":"Reprogramming of somatic cells to induced neural stem cells","volume":"133","author":"Shahbazi","year":"2018","journal-title":"Methods"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.stem.2012.02.021","article-title":"Direct reprogramming of fibroblasts into neural stem cells by defined factors","volume":"10","author":"Han","year":"2012","journal-title":"Cell Stem Cell"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Zhu, W., Mao, Y., and Zhou, L.F. (2005). Reduction of neural and vascular damage by transplantation of VEGF-secreting neural stem cells after cerebral ischemia. Intracranial Pressure and Brain Monitoring XII, Springer.","DOI":"10.1007\/3-211-32318-X_80"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3994","DOI":"10.3390\/ijms21113994","article-title":"Clinical Trials of Stem Cell Treatment for Spinal Cord Injury","volume":"21","author":"Kazuyoshi","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1161\/STROKEAHA.120.030618","article-title":"Cell-based therapy for stroke: Musing with muse cells","volume":"51","author":"Park","year":"2020","journal-title":"Stroke"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/978-4-431-56847-6_18","article-title":"Future of Muse cells","volume":"Volume 1103","author":"Young","year":"2018","journal-title":"Muse Cells"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.jgeb.2018.09.002","article-title":"Recent advances in stem cells therapy: A focus on cancer, Parkinson\u2019s and Alzheimer\u2019s","volume":"16","author":"Fleifel","year":"2018","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.33425\/2639-9512.1058","article-title":"Alzheimer\u2019s disease treated with autologous and allogeneic telomerase-positive stem cells","volume":"5","author":"Young","year":"2021","journal-title":"Stem Cells Regen Med."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Serrenho, I., Rosado, M., Dinis, A., Cardoso, C.M., Gr\u00e3os, M., Manadas, B., and Baltazar, G. (2021). Stem cell therapy for neonatal hypoxic-ischemic encephalopathy: A systematic review of preclinical studies. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063142"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"113086","DOI":"10.1016\/j.expneurol.2019.113086","article-title":"Stem cell-based therapies for Duchenne muscular dystrophy","volume":"323","author":"Sun","year":"2020","journal-title":"Exp. Neurol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Shen, O.Y., Chen, Y., Xu, H., and Lee, C. (2021). The efficacy of na\u00efve versus modified mesenchymal stem cells in improving muscle function in duchenne muscular dystrophy: A systematic review. Biomedicines, 9.","DOI":"10.3390\/biomedicines9091097"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/scrt79","article-title":"Therapeutic effects of human umbilical cord blood-derived mesenchymal stem cells after intrathecal administration by lumbar puncture in a rat model of cerebral ischemia","volume":"2","author":"Lim","year":"2011","journal-title":"Stem Cell Res. Ther."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s13287-015-0240-9","article-title":"The challenges and promises of allogeneic mesenchymal stem cells for use as a cell-based therapy","volume":"6","author":"Zhang","year":"2015","journal-title":"Stem Cell Res. Ther."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:41:23Z","timestamp":1760143283000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/23\/19\/11453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,28]]},"references-count":64,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["ijms231911453"],"URL":"https:\/\/doi.org\/10.3390\/ijms231911453","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,28]]}}}